Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was downgraded by JMP Securities to a “market perform” rating in a research report issued on Thursday, The Fly reports.

Other equities research analysts also recently issued research reports about the company. Oppenheimer Holdings, Inc. set a $28.00 price target on Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, June 12th. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. Zacks Investment Research downgraded Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Syros Pharmaceuticals in a research report on Tuesday, May 16th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Syros Pharmaceuticals presently has an average rating of “Buy” and an average target price of $20.67.

Shares of Syros Pharmaceuticals (SYRS) opened at 22.84 on Thursday. Syros Pharmaceuticals has a 12 month low of $8.47 and a 12 month high of $24.38. The company’s 50-day moving average price is $19.20 and its 200-day moving average price is $15.28. The company’s market cap is $597.95 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Monday, May 15th. The company reported ($0.49) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $1.10 million for the quarter. Analysts anticipate that Syros Pharmaceuticals will post ($2.16) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/syros-pharmaceuticals-inc-syrs-rating-lowered-to-market-perform-at-jmp-securities.html.

In other news, insider Eric R. Olson sold 2,500 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $23.59, for a total transaction of $58,975.00. Following the transaction, the insider now directly owns 2,500 shares of the company’s stock, valued at $58,975. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard A. Young sold 3,282 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total value of $72,499.38. Following the transaction, the director now directly owns 423,383 shares in the company, valued at $9,352,530.47. The disclosure for this sale can be found here. Insiders have sold 18,282 shares of company stock worth $404,599 over the last ninety days.

Several hedge funds and other institutional investors have recently made changes to their positions in SYRS. Bank of New York Mellon Corp boosted its position in shares of Syros Pharmaceuticals by 157.9% in the second quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock worth $483,000 after buying an additional 18,382 shares during the period. Rhumbline Advisers bought a new position in shares of Syros Pharmaceuticals during the second quarter worth about $198,000. Schwab Charles Investment Management Inc. bought a new position in shares of Syros Pharmaceuticals during the second quarter worth about $343,000. Redmile Group LLC boosted its position in shares of Syros Pharmaceuticals by 0.5% in the first quarter. Redmile Group LLC now owns 952,740 shares of the company’s stock worth $15,177,000 after buying an additional 4,300 shares during the period. Finally, Wells Fargo & Company MN bought a new position in shares of Syros Pharmaceuticals during the first quarter worth about $225,000. 49.45% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

The Fly

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.